IQVIA Holdings Inc. $IQV Shares Purchased by Calamos Advisors LLC

Calamos Advisors LLC boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 268.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 188,707 shares of the medical research company's stock after acquiring an additional 137,441 shares during the period. Calamos Advisors LLC owned 0.11% of IQVIA worth $42,536,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in IQV. Brighton Jones LLC lifted its holdings in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock valued at $703,000 after acquiring an additional 2,537 shares during the last quarter. Empowered Funds LLC lifted its stake in IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company's stock worth $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in IQVIA during the second quarter worth $514,000. First Trust Advisors LP lifted its stake in IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company's stock worth $14,501,000 after purchasing an additional 11,845 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its stake in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company's stock worth $3,582,000 after purchasing an additional 1,155 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on IQV shares. Mizuho set a $215.00 price target on IQVIA in a research note on Monday, February 23rd. Weiss Ratings restated a "hold (c)" rating on shares of IQVIA in a research note on Tuesday. Morgan Stanley set a $240.00 price target on IQVIA in a research note on Wednesday, February 11th. TD Cowen upgraded IQVIA from a "hold" rating to a "buy" rating and increased their price objective for the company from $174.00 to $213.00 in a research note on Monday, March 9th. Finally, UBS Group reduced their price objective on IQVIA from $280.00 to $240.00 and set a "buy" rating on the stock in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, IQVIA presently has an average rating of "Buy" and an average target price of $226.63.

IQVIA Stock Up 1.1%

Shares of NYSE IQV opened at $162.48 on Friday. The stock has a market cap of $27.57 billion, a P/E ratio of 20.67, a PEG ratio of 1.60 and a beta of 1.39. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The business's fifty day simple moving average is $170.03 and its 200-day simple moving average is $202.71.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analysts' expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities analysts predict that IQVIA Holdings Inc. will post 11.5 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.